Non-Small Cell Lung Cancer


SK Biopharma and twoXAR Enter Into Discovery and Development Agreement for First-in-Class Treatments for Non-Small Cell Lung Cancer Using AI technology

 SK Biopharma, (Pangyo, South Korea)  and twoXAR (Mountain View, CA.) announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer. Under the agreement, twoXAR will use its AI discovery technology to identify a set of...